Home Blog of Signal Transduction Angiogenesis BTK

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

BTK

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies

10 views | May 18 2022

Chiara Briani et al. found that Class IV evidence that for a patient with relapsed anti-MAG antibody polyneuropathy, MYD88 wild-type, venetoclax plus rituximab was effective. [Read the Full Post]

CDK4/6 inhibitor enhances the radiosensitization of esophageal squamous cell carcinoma (ESCC) by activating autophagy signaling via the suppression of mTOR

38 views | Apr 17 2022

Wen-Jun Qin et al. found that palbociclib improved the radiosensitivity of ESCC in vivo and in vitro, and thus it might be a promising radiosensitization agent for the treatment of ESCC. [Read the Full Post]

Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia

101 views | Feb 19 2022

Miklos Egyed et al. showed a high rate of molecular remission without an impaired safety profile. Adverse events, with an occurrence rate of >20%, were as follows: grade 1-2 myelosuppression, gastrointestinal toxicity, rash, constitutional symptoms; grade 3 or 4 toxicities were syncope, pneumonia, hypertension, atrial fibrillation, neutropenia and thrombocytopenia. [Read the Full Post]

Acalabrutinib CYP3A mediated Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to inform dose adjustment strategy

64 views | Feb 18 2022

Buyun Chen et al. suggested that current PBPK model could be used to propose dose adjustment for drug interactions via CYP3A. [Read the Full Post]

Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy

851 views | Jun 27 2021

Joshua N Gustine et al. revealed that continuation of ibrutinib until subsequent treatment was associated with improved disease control and clinical outcomes. [Read the Full Post]

Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer

359 views | May 14 2021

Muriel Lainé et al. reported for the first time the anti-tumor activity of lasofoxifene in mouse models of endocrine therapy-resistant breast cancer. [Read the Full Post]

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

333 views | May 01 2021

Natalia Timofeeva et al. found a new standard of care for CLL is expected to emerge from these investigations. [Read the Full Post]

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease

296 views | Apr 30 2021

Philipp von Hundelshausen et al. thought that specific platelet function tests in blood might help to estimate the probability of bleeding of newly developed BTKi. [Read the Full Post]

BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib

274 views | Mar 01 2021

H Yesid Estupiñán et al. found that reversible inhibitors showed a variable pattern, from resistance to no resistance, collectively demonstrating the structural constraints for different classes of inhibitors, which might affect their clinical application. [Read the Full Post]

The role of acalabrutinib in adults with chronic lymphocytic leukemia

308 views | Feb 28 2021

Bita Fakhri et al. demonstrated superiority of the acalabrutinib-containing arms in terms of both efficacy and tolerability. [Read the Full Post]